News

Releases included below may include references to both on-label and off-label usage of the HeartLight® Endoscopic Ablation System.
04
Feb
2020
04 Feb 2020

CardioFocus® Announces U.S. FDA PMA Supplement Submission for the Breakthrough HeartLight X3 Endoscopic Ablation System

MARLBOROUGH, Mass., February 4, 2020 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced that the company has submitted a pre-market approval (PMA) supplement to the U.S. Food and Drug Administration (FDA) for the HeartLight X3 Endoscopic Ablation System for the treatment of AFib. This supplement […]

22
Jan
2020
22 Jan 2020

CardioFocus® Names Burke T. Barrett as Chief Executive Officer

MARLBOROUGH, Mass., January 22, 2020 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that the Company’s Board of Directors has promoted Burke T. Barrett to the position of Chief Executive Officer (CEO), effective January 19, 2020. Mr. Barrett previously served as CardioFocus’ President and Chief […]

29
Oct
2019
29 Oct 2019

CardioFocus® Treats First Patients with HeartLight® Endoscopic Ablation System in France

MARLBOROUGH, Mass., October 29, 2019 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that the first patients in France have been treated at the Centre Hospitalier Régional Universitaire (CHRU) of Nancy with the HeartLight® Endoscopic Ablation System as part of an exclusive distribution partnership with MicroPort CRM […]

18
Jun
2019
18 Jun 2019

CardioFocus® Launches 100th HeartLight® Center Worldwide

MARLBOROUGH, Mass., June 18, 2019 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that the HeartLight® Endoscopic Ablation System is now offered at more than 100 hospitals worldwide.

28
May
2019
28 May 2019

CardioFocus® Secures $55 Million In Financing

MARLBOROUGH, Mass., May 28, 2019 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced the completion of a $55 million round of financing.

10
May
2019
10 May 2019

CardioFocus® Announces Impressive Results From Pivotal Confirmatory Study With The Breakthrough HeartLight® X3 System

MARLBOROUGH, Mass., May 10, 2019 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3 System for the treatment of AFib.

25
Mar
2019
25 Mar 2019

CardioFocus® Announces European CE Mark Approval Of Breakthrough HeartLight® X3 System For The Treatment Of Atrial Fibrillation

MARLBOROUGH, Mass., Mar. 25, 2019 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System.

05
Mar
2019
05 Mar 2019

CardioFocus® Initiates Persistent Atrial Fibrillation Study With The Breakthrough HeartLight® X3 System

MARLBOROUGH, Mass., Mar. 5, 2019 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced the first enrollments in a clinical study evaluating use of the HeartLight X3 System in an early persistent AFib patient population. The 60 patient, prospective study will be led by Na Homolce Hospital (NHH) […]

11
Jul
2018
11 Jul 2018

CardioFocus® Announces Full Commercial Launch of HeartLight® System in Japan

MARLBOROUGH, Mass., July 11, 2018 /PRNewswire/ — CardioFocus, Inc., a medical device innovator and manufacturer dedicated to advancing ablation treatment for atrial fibrillation (AF), today announced the commercial launch of its HeartLight Endoscopic Ablation System in Japan. The commercial launch will be managed in conjunction with its distribution partner JapanLifeline Co., Ltd. (JLL).

14
May
2018
14 May 2018

CardioFocus® Announces Successful Live Case Featuring HeartLight® X3 System

MARLBOROUGH, Mass., May 9, 2018 /PRNewswire/ — CardioFocus, Inc., a medical device innovator and manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF), today announced a successful live case featuring its breakthrough HeartLight X3 System during the annual Prague Workshop on Catheter Ablation.